Clinical Trial News and Research

RSS

B-complex vitamins slow down mild cognitive impairment

Large doses of B-complex vitamins could reduce the rate of brain shrinkage by half in elderly people with memory problems and slow the progression of dementia.

25 Oct 2010

Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia

Inviragen, a company developing vaccines to protect against infectious diseases worldwide, and the Program for the Study and Control of Tropical Diseases (PECET), jointly announced the initiation of a Phase 1 clinical trial of DENVax™ in Colombia. DENVax is an investigational vaccine designed to provide protection against all four dengue virus serotypes. The trial will measure the safety of DENVax as well as the immune responses induced by the vaccine in healthy adults in Rionegro, Colombia.

25 Oct 2010

First implantation of Neo-Urinary Conduit in bladder cancer patient performed at University of Chicago

Tengion, Inc., a leader in regenerative medicine, announced today that surgeons at the University of Chicago have implanted its Neo-Urinary Conduit™ in the first patient as part of the ongoing clinical trial evaluating the Company's lead product candidate in bladder cancer patients requiring a urinary diversion following bladder removal.

25 Oct 2010

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Alkermes, Inc. today announced positive topline results from a phase 1 clinical study of an investigational combination of ALKS 33, one of Alkermes' proprietary candidates, and buprenorphine, an existing medication for the treatment of opioid addiction, for the treatment of cocaine addiction.

25 Oct 2010

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Immune Network Ltd. advises that a clinical trial of V5 Immunitor oral vaccine was published earlier this month demonstrating an unexpected powerful effect against tuberculosis, including multi-drug-resistant tuberculosis (MDR-TB) and tuberculosis that is complicated by co-infection with HIV and hepatitis C (HCV).

25 Oct 2010

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010

DATATRAK announces 2010 Q4 release of eClinical solution

DATATRAK International, Inc. a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the 2010 Q4 release of its DATATRAK eClinical solution.

25 Oct 2010

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.

25 Oct 2010

Research finds succimer drug not effective in removing mercury

Succimer, a drug used for treating lead poisoning, does not effectively remove mercury from the body, according to research supported by the National Institutes of Health. Some families have turned to succimer as an alternative therapy for treating autism.

25 Oct 2010

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

25 Oct 2010

UCI scientists receive CIRM grants to improve stem cell treatments

UC Irvine scientists will receive grants totaling $9.35 million to help create stem cell treatments for retinitis pigmentosa, Huntington's disease and traumatic brain injury.

25 Oct 2010

Kryptonite adhesive can improve quality of heart patients recovering from open-chest surgery

New research shows that a surgical procedure using a cutting-edge super glue pioneered a year ago by Calgary researchers can improve the recovery of heart patients recovering from open-chest surgery, Dr. Paul Fedak today told the Canadian Cardiovascular Congress 2010, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

25 Oct 2010

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

UCSF scientists have received two grants from the California Institutefor Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure. The goal of the grants is for researchers to make significant strides toward the development of potential therapies within the next three years.

25 Oct 2010

New multi-centre trial to treat cold and flu in children

Three Canadian research teams are trying to determine if a novel Canadian medicine approved by Health Canada for adults can help parents deal with the hacking coughs and runny noses their children suffer.

22 Oct 2010

UTHealth renewed as 'Center of Excellence' by NIDA

By delivering an innovative, interdisciplinary approach to drug abuse and addiction research, The University of Texas Health Science Center at Houston (UTHealth) has been renewed as a "Center of Excellence" by the National Institute on Drug Abuse, part of the National Institutes of Health.

22 Oct 2010

EES implantation reduces restenosis, repeat revascularization in patients with calcified culprit lesions

Two new studies have determined that everolimus-eluting stent (EES) implantation reduced the incidence of restenosis and repeat revascularization in patients with calcified culprit lesions, and had fewer clinical events. Results show the rate of major cardiac adverse events in EES-treated patients with calcified lesions were higher than in those for noncalcified lesions, but remained lower than the results of previously reported stent studies.

22 Oct 2010

Parents more likely to be dissatisfied with informed consent process in children’s clinical trials

Compared with adult cancer patients, parents of children with cancer were more likely to be dissatisfied with the informed consent process for participating in clinical trials, according to a study from Dana-Farber/Children's Hospital Cancer Center. The findings will be presented at the 42nd Congress of the International Society of Paediatric Oncology (SIOP) in Boston on Saturday, Oct. 23.

22 Oct 2010

Astellas suspends patient enrollment from ACT 5 study of KYNAPID

Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of KYNAPIDTM (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received KYNAPID.

22 Oct 2010

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the 24th Annual North American Cystic Fibrosis Conference (NACFC) October 21-23, 2010 in Baltimore, Maryland.

22 Oct 2010

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

Today, Cephalon, Inc. announced the signing of a convertible note subscription agreement with ChemGenex Pharmaceuticals Limited, an Australian-based oncology focused biopharmaceutical company.

22 Oct 2010

Clinical Trial News and Research

B-complex vitamins slow down mild cognitive impairment

Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia

First implantation of Neo-Urinary Conduit in bladder cancer patient performed at University of Chicago

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

DATATRAK announces 2010 Q4 release of eClinical solution

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

Research finds succimer drug not effective in removing mercury

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

UCI scientists receive CIRM grants to improve stem cell treatments

Kryptonite adhesive can improve quality of heart patients recovering from open-chest surgery

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

New multi-centre trial to treat cold and flu in children

UTHealth renewed as 'Center of Excellence' by NIDA

EES implantation reduces restenosis, repeat revascularization in patients with calcified culprit lesions

Parents more likely to be dissatisfied with informed consent process in children’s clinical trials

Astellas suspends patient enrollment from ACT 5 study of KYNAPID

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer